These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26857277)

  • 1. Immunization Policy and the Importance of Sustainable Vaccine Pricing.
    Meissner HC
    JAMA; 2016 Mar; 315(10):981-2. PubMed ID: 26857277
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.
    MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW
    MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization update: the latest ACIP recommendations.
    Campos-Outcalt D;
    J Fam Pract; 2014 Mar; 63(3):137-40. PubMed ID: 24701599
    [No Abstract]   [Full Text] [Related]  

  • 6. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of meningococcal C conjugate vaccine use in Australia.
    Booy R; Jelfs J; El Bashir H; Nissen MD
    Med J Aust; 2007 Feb; 186(3):108-9. PubMed ID: 17309394
    [No Abstract]   [Full Text] [Related]  

  • 8. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New vaccine recommendations.
    J Fam Health; 2015; 25(5):6. PubMed ID: 26625587
    [No Abstract]   [Full Text] [Related]  

  • 18. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.